Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT

MEMORANDUM OF UNDERSTANDING WITH XtalPi

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

MEMORANDUM OF UNDERSTANDING

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that the Company has recently entered into a memorandum of understanding (the "**MOU**") with XtalPi Holdings Limited ("**XtalPi**"), pursuant to which the parties have agreed to integrate the core strengths of the Company in genomics technology and its vast disease database centered on Asian populations, with XtalPi's leading AI+ robotics drug discovery and research platform. Together, the parties will jointly build an AI-enabled, innovative "integrated diagnosis and intervention" development and commercialization platform for Asian high-incidence cancers, particularly focusing on the early detection and intervention of gastrointestinal cancers. This platform will combine diagnosis and treatment to jointly develop early diagnosis and intervention solutions.

The MOU has a term of two years from and includes the date of signing.

INFORMATION OF XtalPi

XtalPi is an innovative platform-based technology company that leverages quantum physics, artificial intelligence and robotics. It utilizes cutting-edge technologies such as quantum physics, artificial intelligence, cloud computing, and robotic experiments to create an innovative R&D platform for future industries. This platform, with its integrated advantages in common technologies, meets the needs of exploring the microscopic molecular world, achieving significant results in the biopharmaceutical industry and greatly improving R&D efficiency and success rates.

REASONS FOR AND BENEFITS OF THE COLLABORATION UNDER THE MOU

The collaboration under the MOU aligns both the Company's and XtalPi's long-term objectives in advancing early detection and early intervention to help everyone live a healthy life, signaling an important step of the Company to synergize its core early detection tests with potential early intervention solutions to offer a holistic precision medicine approach. By bringing together the complementary strengths of the Company and XtalPi, the collaboration will create meaningful synergies. It will combine the Company's years of extensive high-quality cancer biomedical omics data, resources established in the cancer diagnostics field, and its operational advantages particularly within the Asia-Pacific region, with XtalPi's AI R&D platform cultivated over years of dedicated expertise in the biopharmaceutical sector, its R&D experience in drug development/consumer health, and its capabilities in collecting, cleaning, and developing large-scale biopharmaceutical data cultivated over years. Together, the parties will jointly develop and industrialize an AI-enabled and innovative early diagnosis and intervention solution for high-incidence Asian cancers, particularly focusing on gastrointestinal cancers.

SCOPE OF THE COLLABORATION UNDER THE MOU

The collaborative areas as set out in the MOU are as follows:

(a) construct a global cancer biomedical omics and chemical data center (especially for Asian populations);

(b) discovery and clinical development of new targets related to cancer biomarkers and drug development; and

(c) create an integrated diagnosis and intervention platform for targeting digestive system cancers prevalent in Asia.

The Board is also of the view that this partnership with XtalPi can generate substantial strategic value, which further strengthens the Company's positioning as the anchor for the region's growing RNA diagnostic and therapeutic ecosystem, as well as its leadership in the global market segment for early diagnosis and intervention of gastrointestinal cancers. It will further enhance the Company's product portfolio of early detection and preventive solutions, and early intervention while accelerating the Company's revenue growth. This collaborative, AI-enabled, innovative "integrated diagnosis and intervention" platform enables global institutions to partner with the Company and XtalPi in accessing and advancing regional opportunities, while simultaneously enabling the Company and XtalPi to strategically enter the Asian market. The collaboration is also expected to enhance corporate visibility, deepen research and development capabilities, and contribute to the Group's long-term growth and revenue diversification.

Shareholders and potential investors of the Company should note that the collaboration under the MOU may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, December 5, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.